Application of the ELISPOT assay to the monitoring of changes in the number of LCL-responsive CD8⁺ cells following adoptive CTL infusion.

Two patients with PTLD received EBV-specific polyclonal CTL infusion from partially matched donors. The HLA types of patients and donors were: patient 1 (A1, 24, B7, 8), donor for patient 1 (A1, 33, B8, 17); patient 2 (A2, 32, B13, 27), donor for patient 2 (A2, 3, B7, 27). Blood was drawn immediately before and at the indicated time points after infusion. CD8⁺ cells were used as responders in ELISPOT assays with the patient's LCLs as stimulators. Each bar represents the mean ± SD of triplicate wells.